On October 15, 2019 Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics, clinical lab, and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, reported results for the fiscal fourth quarter and year ended July 31, 2019 (Press release, Enzo Biochem, OCT 15, 2019, View Source [SID1234542260]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company reports progress in the three core pillars of its value creation strategy: strategic relationships for growth, creating a new paradigm for the laboratory diagnostic marketplace and returning to operating profitability and growth in the lab segment of the business. In furtherance of these objectives, Enzo has retained Lazard to assist in the previously announced initiative to form strategic relationships or new venture creation across the Company’s four core platforms: molecular, immunohistochemistry, cytology and immunology.

Highlights for the Quarter and Full Year

•Enzo’s vertically integrated research and development program, harnessing the collective benefits of its laboratory and diagnostic operations, continued to deliver substantial technological advances. By leveraging its broad intellectual property portfolio and manufacturing expertise, Enzo is able to create novel products and platforms with the potential to be transformative to diagnostic products and services.

•In September, Enzo Clinical Labs, Inc., received New York State Department of Health approval for its AMPIPROBE HBV viral load monitoring assay for Hepatitis B virus (HBV) based on performance versus an FDA-approved competitive product. Enzo’s growing portfolio in the viral load monitoring market includes previous New York State Department of Health approval for a viral load monitoring assay for Hepatitis C virus (HCV) and a viral load monitoring assay under development for human immunodeficiency virus (HIV). The Company’s expanding menu allows Enzo to provide one of the most comprehensive panels for sexually transmitted infections (STI) testing, a rapidly growing healthcare segment where reported common STIs in the US have increased for the 5th consecutive year.

•Approval of the HBV assay follows the July announcement of New York State Department of Health approval for Gonorrhea and Chlamydia tests for extragenital specimens, and the announcement that Enzo was creating a direct to consumer testing business for STIs. Furthermore, the Company is developing an additional test for HPV testing in multiple sample types.

•The Company was issued 74 patents worldwide during fiscal year 2019. Notably, the Company was issued U.S. Patent No. 10,323,272 entitled "Nucleic acid probes for in situ hybridization" on June 18, 2019, which is directed to a new probe technology that allows for significantly more cost effective, simple and scalable processes across the multi-billion dollar diagnostic testing, drug development and academic research marketplaces. The probes can be used to detect clinically relevant genomic targets with high sensitivity in cell samples and biopsy tissue. Compared to competitive probes, Enzo’s novel probe will lower cost, decrease complexity, save time and avoid disruptions of sample integrity.

·In fiscal year 2019, Enzo’s Life Sciences and laboratory divisions invested approximately $10 million in strategic growth initiatives such as developing a Good Manufacturing Practice (GMP) Lab, expanding strategic salesforce and marketing practices, and ramping up R&D and Lab Developed Test initiatives. This investment is already resulting in cost reductions for the laboratory and diagnostics operations. Currently, approximately $4M of the Company’s revenue is associated with strategic growth initiatives.

·Over the past 5 years, Enzo has systematically introduced its technology onto its clinical production floor through LDTs validated by the New York State Department of Health. Over this period, Enzo has run over 100,000 of these Enzo LDTs, resulting in savings of over $5M by substituting third-party vendor tests with Enzo’s own internally developed tests. Enzo expects the annual savings from these tests to increase in the next fiscal year to $3M and to $5M in the following year.

Elazar Rabbani, PhD., Chairman and Chief Executive Officer, Comment:

"Enzo’s structure and business strategy represent the culmination of years of extensive planning and productive work. The Company has the ability to offer low cost, high performance products and services in molecular diagnostics. While reimbursement pressures facing diagnostic labs

remain a headwind in the short term, our unique offering positions us well to capitalize on these secular trends over the long term. Our pioneering work in genomic analysis coupled with our extensive patent estate and enabling platforms have positioned the Company to continue to play an important role in the rapidly growing molecular medicine marketplaces.

"Enzo technology solutions and platforms and unique operational structure are designed to reduce overall healthcare costs for both government and private insurers. Our proprietary technology platforms reduce our current and prospective customers’ needs for multiple, specialized instruments, and offer a variety of high throughput capabilities together with a demonstrated high level of accuracy and reproducibility. Our genetic test panels are focused on large and growing markets primarily in the areas of personalized medicine, women’s health, infectious diseases and genetic disorders.

"Our Company continues to make significant progress toward unlocking shareholder value, guided by the three core pillars of our strategy – strategic relationships, creating a new paradigm for the laboratory and diagnostic marketplaces, and returning to operating profitability and lab segment growth. One of our chief goals, as we’ve stated previously, is to achieve clinical laboratory profitability despite a very challenging reimbursement environment. We feel confident we are on track towards accomplishing this objective."

"Testing activity and volume is up sequentially this quarter, as overall lab revenues grew 11% in the fourth quarter vs. the third quarter of fiscal 2019. Our expanding panel of STI testing, enhanced by a recent diagnostic test approval, is one of the most extensive available, including the highly comprehensive women’s health diagnostic panel.

"Our diagnostic products, developed and manufactured at Enzo Life Sciences, and formatted and validated at Enzo Clinical Labs, are perfect examples of the integrated nature of our Company’s businesses and the value and leverage we generate from these synergies. It would be extremely difficult and costly to replicate as two separate units and more importantly, this combination demonstrates the real time benefits that labs around the country can achieve as the result of our work. In an adverse laboratory-wide climate of shrinking margins and declining profitability, our proprietary platforms that offer high sensitivity, compatibility with existing systems and low cost/higher margins, are tailor-made for both product sales and the lab-to-lab growth opportunities that we are actively pursuing.

"This active, commercial installation in our Lab is attracting increasing attention among major as well as smaller players who are showing meaningful enthusiasm for our platforms and products. Discussions with leading life sciences and medical device companies as well as manufacturers of automated systems of our molecular diagnostics, immunohistochemistry and ELISA platform are progressing well. We expect to update the market by the end of the calendar year on these discussions."

Fourth Quarter Operating Results

·Total revenues amounted to $21.0 million, compared to $22.8 million in the year ago period, a decline of 8% reflecting new, sharply lower industry-wide Protecting Access to Medicare Act reimbursement rates; sequential total testing volume increased 4%. Sequentially, clinical laboratory services revenues increased 11% from the prior quarter’s $11.8 million, while product revenues for the quarter were up 3% over the prior year period as a result of the successful implementation of new marketing and sales initiatives. Lab revenues declined to $13.1 million, from $15.1 million in the year ago period, due to the reduced insurance reimbursement payments and changes to medical and procedural requirements for genetic testing by payors. Overall, gross profit improved sequentially by 21%, to $6.3 million, with clinical lab gross profit more than doubling to $1.8 million, from $0.8 million, and product gross margin increasing 2% to $4.6 million.
· As noted previously, clinical services revenues for the fourth quarter and full year ended July 31, 2019, reflect adoption of new revenue recognition accounting rules on a full retrospective basis. Under the new rules, Enzo reports uncollectible balances associated with patient responsibility as a reduction in net revenues; historically these amounts were separately classified in operating expenses as a provision for uncollectible accounts receivable, and amounted to $3.1 million and $3.7 million, respectively in the fiscal years ended July 31, 2019 and 2018, and $1.0 million and $1.7 million for the respective fourth quarter periods.
·Consolidated gross margins for the quarter of 30.3% compared with 35.2% a year ago, and up 300 basis points sequentially. Clinical services gross margins were 13.8% compared to 25.4% a year ago and sequentially improved from in the third quarter. The improvement reflected both higher testing volume and enhanced efficiency. Product gross margin for the quarter increased to 58%, from 54%, and sequentially was up 200 basis points.
·Operating expenses declined 12%, or $1.6 million to $12.0 million year over year, and sequentially remained flat, adjusted for net legal settlements. Legal fee expenses declined by $1.0 million compared to the fourth quarter last year, to $0.3 million, and sequentially were flat in both periods.
·GAAP net loss was ($5.4) million, or ($0.11) per share, an improvement of 7% compared with a year ago quarter net loss of ($5.8) million, or ($0.12) per share. The non-GAAP net loss was ($5.4) million, compared to ($5.8 million) a year ago and ($6.7) million in the preceding quarter. On a per share basis, the non-GAAP loss equaled ($0.11), compared with ($0.12) a year ago and ($0.14) in 3Q19 on an adjusted basis. EBITDA loss in the quarter and a year ago approximated ($5.0) million and ($5.3) million respectively and decreased sequentially from ($6.1) million on an adjusted basis.

Full Year Operating Results

Total revenues were $81.2 million compared to $101.0 million, a year ago, a decline of 20%, and as noted earlier reflected newly instituted reduced reimbursement payments, insurance company claims rejections and changes to medical and procedural requirements for genetic testing by

payors. Gross profit was $23.2 million, compared to $40.7 million the prior year, with gross margins at 28.6% and 40.3%, respectively. Legal fees declined by 41%, to $3.0 million, and tailed off sharply towards year end, while SG&A declined to $44.2 million from $44.5 million. GAAP net income amounted to $2.5 million, or $0.05 per diluted share, compared to a net loss of ($10.3) million, or ($0.22) per share, a year earlier. Non-GAAP net loss amounted to ($26.4) million, net of legal settlements, compared to a non-GAAP fiscal 2018 net loss of approximately ($11.4) million. EBITDA was $4.5 million, compared to year ago EBITDA loss of ($9.1) million.

At year-end, cash, cash equivalent and restricted cash totaled $60.9 million, and working capital amounted to $65.4 million.

Conference Call

The Company will hold a conference call on Tuesday, October 15, 2019, at 4:30 PM E.T. To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. When prompted, use PIN number 4196818.

Interested parties may also listen over the Internet at: View Source

To listen to the live call, individuals should go to the website at least 15 minutes early to register, download and install any necessary audio software. Any pop up blocker installed on your PC should be disabled while accessing the webcast. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through 12 AM (E.T.) Tuesday October 29, 2019. The replay of the conference call can be accessed by dialing 1-855-859-2056 (International callers can dial 1-404-537-3406) and, when prompted, use the same PIN number 4196818.

On October 15, 2019 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported Jarrod Longcor, chief business officer of Cellectar, presented a poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology, being held from October 15 – 17, 2019 in London, United Kingdom (Press release, Cellectar Biosciences, OCT 15, 2019, View Source [SID1234542259]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster, entitled: "Phospholipid ether delivery vehicle shows specificity for a broad range of tumor cells and provides a novel and improved approach for targeted therapy," featured data demonstrating that phospholipid ether drug conjugates (PDCs) were capable of delivering small molecule cytotoxins selectively to tumor cells and were well tolerated in animal models. In the data presented, all animals exposed to a single infusion of the payload alone died, while all animals receiving multiple doses with the PDCs survived with no adverse effects observed at all dose levels tested. Additionally, PDCs showed rapid uptake and release of 20% to 40% of the conjugate and payload in a wide range of tumor cells. The PDCs also demonstrated potent activity against the tumor cells with inhibitory concentrations in the low nanomolar range.

"PDCs are an exciting novel class of targeted oncology agents with a unique method of action that offers an attractive alternative to antibody drug conjugates," said Jarrod Longcor, chief business officer of Cellectar. "The ability to deliver up to 40% of the PDCs to the tumor versus less than 1% for antibody drug conjugates means that some payloads that previously could not be delivered to tumor cells in high enough amounts may now be delivered at levels that could result in activity. Additionally, the demonstration of activity and tolerability is a major milestone in the development of our PDC programs."

About Phospholipid Drug Conjugates

Cellectar’s product candidates are built upon a patented delivery and retention platform that utilizes optimized phospholipid ether-drug conjugates (PDCs) to target cancer cells. The PDC platform selectively delivers diverse oncologic payloads to cancerous cells and cancer stem cells, including hematologic cancers and solid tumors. This selective delivery allows the payloads’ therapeutic window to be modified, which may maintain or enhance drug potency while reducing the number and severity of adverse events. This platform takes advantage of a metabolic pathway utilized by all tumor cell types in all cell cycle stages. Compared with other targeted delivery platforms, the PDC platform’s mechanism of entry does not rely upon specific cell surface epitopes or antigens. In addition, PDCs can be conjugated to molecules in numerous ways, thereby increasing the types of molecules selectively delivered. Cellectar believes the PDC platform holds potential for the discovery and development of the next generation of cancer-targeting agents.

On October 15, 2019 Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, reported the presentation of updated clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the first line treatment of primary choroidal melanoma, at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting, being held October 12-15, 2019 in San Francisco, CA (Press release, Aura Biosciences, OCT 15, 2019, View Source [SID1234542258]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With its ability to provide tumor control and vision preservation, AU-011 holds significant potential as a new targeted therapy for the primary treatment of choroidal melanoma," said Cadmus Rich, MD, Chief Medical Officer and Head of Research and Development of Aura Biosciences. "The data presented this year by Dr. Duker provided information on Aura’s proprietary technology platform and key insights that will inform the design and conduct of our pivotal Phase 3 program for AU-011, which we expect to commence in the second half of 2020. Dr. Schefler’s presentation included an update on ongoing research we are conducting into suprachoroidal delivery which, may allow us to increase the range of tumor sizes that AU-011 can treat. Both of these presentations underscore our long-term vision and commitment to bringing this first-in-class technology to patients for this rare and life-threatening disease."

Updated Results from the Phase 1b/2 Study Evaluating AU-011

Jay S. Duker, M.D., Director New England Eye Center, and Professor and Chair, Tufts Medical Center, gave an oral presentation titled, "Novel Management of Choroidal Melanoma – AU-011," which highlighted the potential of Aura’s viral like particle technology, updated data from the ongoing open-label Phase 1b/2 clinical trial, and described the novel design of the planned Phase 3 trial that Aura expects to initiate during the second half of 2020.

The Phase 1b/2 clinical data presented at AAO demonstrate that multiple administrations of light-activated AU-011 were well-tolerated. Among the patients evaluated for safety (n=46), the most common treatment-related adverse events (AEs) were expected and included anterior chamber inflammation, posterior chamber inflammation and increase in intraocular pressure; all were manageable with standard-of-care treatments and the majority resolved without clinical sequelae. Notably, the posterior inflammation appears to originate within and/or around the tumor which is consistent with AU-011’s mechanism of action of acute tumor necrosis. There was one treatment-related severe AE (vision loss; 2%) in one patient with a juxtafoveal tumor.

Tumor control and vision preservation data continue to be supportive of the planned Phase 3 registration trial. In the subset of patients with documented tumor growth prior to trial enrollment (n=17), treatment with AU-011 resulted in tumor control in 15 patients (88%; p=0.0117). The results from this ongoing Phase 1b/2 study will inform the design of Aura’s planned pivotal Phase 3 program for AU-011.

"The data presented this year at AAO show that AU-011 is well tolerated with early signals of efficacy," said Dr. Duker. "AU-011 is administered via a simple, two-step procedure which includes an intravitreal injection followed by a laser application; all of which is completed in the physician’s office. If approved, AU-011 represents the first potential new treatment for choroidal melanoma in several decades."

Exploring Suprachoroidal Delivery for AU-011

Amy C. Schefler, M.D., Weill Cornell Medical College and Retina Consultants of Houston, gave an oral presentation highlighting the data from the ongoing Phase 1b/2 study with intravitreal administration as well as new preclinical research demonstrating the potential advantages of delivering AU-011 using the suprachoroidal route of administration. Aura recently executed a licensing agreement with Clearside Biomedical for use of Clearside’s suprachoroidal space (SCS) Microinjector for the treatment of intraocular cancers. Aura believes that by delivering AU-011 into the SCS, there is the potential for treating a larger number of patients with a good safety profile and a greater range of tumor sizes. Preliminary preclinical pharmacology data showed that AU-011 administered via the SCS Microinjector achieved full necrosis of tumor cells in all animals following laser activation. Further preclinical studies are currently ongoing and Aura expects to initiate clinical testing using suprachoroidal delivery for AU-011 during the first half of 2020.

About Choroidal Melanoma

Choroidal melanoma is a rare and aggressive type of eye cancer. Choroidal melanoma is the most common primary intraocular tumor in adults and develops in the uveal tract of the eye. No targeted therapies are available at present, and current radiotherapy treatments can be associated with severe visual loss and other long-term sequelae such as dry eye, glaucoma, cataracts and radiation retinopathy. The most common current treatment is plaque radiotherapy, which involves surgical placement of a radiation device on the exterior of the eye over the tumor. The alternative is enucleation, or total surgical removal of the eye. Choroidal melanoma metastasizes in approximately 50 percent of cases with liver involvement in 80-90% of cases and, unfortunately, metastatic disease is universally fatal (source: OMF). There is a very high unmet need for a new vision sparing targeted therapy that could enable early treatment intervention for this life-threatening rare disease given the lack of approved therapies, and the comorbidities of radioactive treatment options.

About Light-Activated AU-011

AU-011 is a first-in-class targeted therapy in development for the treatment of primary choroidal melanoma. The therapy consists of proprietary viral-like particle bioconjugates (VPB) that are activated with an ophthalmic laser. The VPBs bind selectively to unique receptors on cancer cells in the eye and are derived from technology originally pioneered by Dr. John Schiller of the Center for Cancer Research at the National Cancer Institute (NCI), recipient of the 2017 Lasker-DeBakey Award. Upon activation with an ophthalmic laser, the drug rapidly and specifically disrupts the cell membrane of tumor cells while sparing key eye structures, which may allow for the potential of preserving patients’ vision and reducing other long-term complications of radiation treatment. AU-011 can be delivered using equipment commonly found in an ophthalmologist’s office and does not require a surgical procedure, pointing to a potentially less invasive, more convenient therapy for patients and physicians. AU-011 for the treatment of choroidal melanoma has been granted orphan drug and fast track designations by the U.S. Food and Drug Administration and is currently in clinical development.

On October 15, 2019 Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, reported that the first patient has been enrolled in its registration-directed, randomized, controlled Phase 2 clinical trial of RP1 in combination with Regeneron and Sanofi’s Libtayo (cemiplimab-rwlc) compared to Libtayo alone in patients with cutaneous squamous cell carcinoma (CSCC) (Press release, Replimune, OCT 15, 2019, View Source [SID1234542256]). The Company also announced plans to initiate a new clinical trial of RP1 as monotherapy in organ transplant recipients with CSCC in early 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to announce the initiation of our first registration-directed clinical trial for which we believe the data generated to date for RP1 in CSCC is strongly supportive," said Robert Coffin, Ph.D., President and CEO of Replimune. "Having reviewed the initial data in CSCC, we also intend to initiate a new clinical trial of single agent RP1 in organ transplant recipients with CSCC, which we expect to begin enrolling early next year."

The registration-directed Phase 2 clinical trial in CSCC is a multi-center, randomized, controlled clinical trial intended to enroll approximately 240 patients. The study’s primary objective is to compare the response rate following treatment with RP1 in combination with Libtayo to the response rate achieved with Libtayo alone. Libtayo is an anti-PD-1 therapy developed by Regeneron and Sanofi, which was approved by the U.S. Food and Drug Administration (FDA) last year for the treatment of patients with metastatic CSCC or locally-advanced CSCC who are not candidates for curative surgery or curative radiation. This clinical trial is being conducted under the Company’s collaboration agreement with Regeneron. The first patient in the trial has now been enrolled, and multiple clinical trial sites in the U.S. and Australia are open for enrollment. Additional clinical trial sites in these and other countries will be added, with recruitment expected to take approximately 18 to 24 months.

New Clinical Trial Planned of RP1 as Monotherapy in Organ Transplant Recipients with CSCC

Replimune intends to initiate a new Phase 1b clinical trial of single agent RP1 in organ transplant recipients with CSCC, for which the clinical trial protocol has been accepted by the FDA under the Company’s Investigational New Drug application. This clinical trial is intended to enroll approximately 30 patients and assess the safety and efficacy of RP1 in liver and kidney transplant recipients with recurrent CSCC, and is expected to initiate in the first quarter of 2020.

"CSCC is a significant unmet medical need in organ transplant recipients, where it is the most prevalent tumor type in an immunosuppressed population already at higher risk for malignancy in general, and where anti-PD1 therapy provides a significant risk of rejection of the transplanted organ," said Howard Kaufman, MD, Chief Medical Officer of Replimune. "We believe that single agent RP1 has the potential to address a significant unmet need for these patients."

Initial Clinical Data with RP1 Strongly Supports the Company’s Programs in CSCC

The Phase 1 part of Replimune’s Phase 1/2 clinical trial of RP1 enrolled 36 patients with advanced heavily pre-treated cancers who have failed available therapy, evaluating treatment with RP1 alone given up to five times, and RP1 given up to eight times in combination with Opdivo (nivolumab) from the second RP1 dose. Following completion of the Phase 1 part of the clinical trial, the Company opened enrollment for Phase 2 cohorts of 30 patients each in patients with melanoma, non-melanoma skin cancers, bladder cancer, and MSI-H tumors. Five patients with CSCC have been enrolled and treated with RP1 combined with Opdivo in this clinical trial, including one from the Phase 1 expansion in combination with Opdivo, and four from the Phase 2 non-melanoma skin cancer cohort. Initial results in these CSCC patients showed:

The first patient achieved a biopsy-confirmed complete response (CR) of extensive disease of the scalp. Clear tumor flattening was observed after the first dose of RP1 and prior to the first dose of Opdivo, prior to the patient ultimately achieving a CR. PD-L1 and CD8 T cell levels were also substantially increased post-treatment as compared to baseline (this data remains pending for the other patients).
The second patient achieved a partial response (PR) of bulky bi-lateral disease in the neck, with substantial reduction observed after the first dose of RP1 and prior to the first dose of Opdivo, including of the uninjected tumor contralateral to the injection site.
The third patient had extensive and rapidly progressing metastatic disease and died from disease progression within 6 weeks of starting therapy.
The fourth patient, also with bulky disease in the neck, had a substantial reduction after the first RP1 dose, which continued to reduce following the introduction of Opdivo.
The fifth patient, with recurrent bone invasive CSCC of the cheek, had substantial flattening after the first RP1 dose and has recently initiated the combination therapy phase with RP1 and Opdivo.
All patients other than the third patient continue on treatment.
The data from these patients can be found in the presentation linked here.

"I have been highly impressed by the initial clinical data in patients with CSCC treated with RP1," said Professor Kevin Harrington, PhD, of The Royal Marsden Hospital in the UK who has treated the majority of CSCC patients in the trial. "The clear demonstration of clinical activity in CSCC, particularly the early and rapid tumor reductions seen in patients with advanced disease including prior to the addition of Opdivo, combined with the emerging safety profile, is very encouraging."

The full Phase 1 safety, clinical efficacy and biomarker data from this clinical trial, which Replimune believes further supports the overall clinical development strategy for RP1, is scheduled to be presented at The Society For Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting in National Harbor, Maryland. on November 8, 2019.

About CSCC

CSCC is the second most common form of skin cancer and is responsible for an estimated 7,000 deaths each year in the U.S. It currently accounts for approximately 20% of all skin cancers in the U.S., with the number of newly diagnosed cases expected to rise annually. When CSCC invades deeper layers of the skin or adjacent tissues, it is categorized as locally advanced. Once it spreads to other distant parts of the body, it is considered metastatic. Libtayoâ is the only approved therapy in the United States and Brazil, and conditionally approved therapy in the European Union and Canada, for the treatment of locally advanced or metastatic CSCC.

About CSCC in the Organ Transplant Population

The risk of developing cancer following solid organ transplant has been reported to be between 2- and 4-fold higher than in the general population. This includes increased rates of skin cancer, Hodgkin and non-Hodgkin lymphoma, Kaposi sarcoma, and liver, lung, and thyroid cancers. The cumulative incidence of skin cancers, such as CSCC, increases with time from transplantation, with rates as high as 70% after 20 years. When compared with the general population, organ transplant recipients have a 65- to 250-fold increased risk of developing CSCC and a 2- to 8-fold risk of developing melanoma. In the clinical trials in which immune checkpoint blockade drugs have been investigated, organ transplant patients were excluded due to the potential risk of transplanted organ rejection, and as a result, safety and efficacy has not been formally studied. Safety and efficacy of immune checkpoint blockade drugs in organ transplant recipients has, however, recently been obtained from literature reports including 57 organ transplant patients (Fisher et al 2019 J. Am. Acad. Dermatol. Jul 11 Epub ahead of print). Kidney allograft was the most commonly reported transplant (n = 32), followed by liver (n = 20) and heart (n = 5). While the efficacy of immune checkpoint blockade drugs was consistent with that in the general population, 37% of cases resulted in graft rejection and 14% resulted in death due to rejection of the graft. The highest rate of rejection was seen in patients with kidney transplant (41%), followed by liver (35%) and heart (20%).

About RP1

RP1 is Replimune’s lead Immulytic product candidate and is based on a proprietary new strain of herpes simplex virus engineered to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response.

On October 15, 2019 Perrigo Company plc (NYSE; TASE: PRGO), reported that it will release its third quarter calendar year 2019 financial results on Wednesday, November 6, 2019 (Press release, Perrigo Company, OCT 15, 2019, View Source [SID1234542255]). The Company will host a conference call beginning at 8:00 a.m. (EDT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at View Source or by phone at 888-317-6003, International 412-317-6061, and reference ID 9864625. A taped replay of the call will be available beginning at approximately 12:00 p.m. (EDT) Wednesday, November 6, 2019 until midnight, November 13, 2019. To listen to the replay, dial 877-344-7529, International 412-317-0088, and use access code 10135743.